PATIL, Shivaprasad Gangadhar, 2022. A novel 2-metagene signature to identify high-risk HNSCC patients amongst those who are clinically at intermediate risk and are treated with PORT. Basel: MDPI.
Elsevier - Harvard (with titles)Patil, S.G., 2022. A novel 2-metagene signature to identify high-risk HNSCC patients amongst those who are clinically at intermediate risk and are treated with PORT, Cancers. MDPI, Basel. https://doi.org/10.3390/cancers14123031
American Psychological Association 7th editionPatil, S. G. (ca. 2022). A novel 2-metagene signature to identify high-risk HNSCC patients amongst those who are clinically at intermediate risk and are treated with PORT [Cd]. In Cancers. MDPI. https://doi.org/10.3390/cancers14123031
Springer - Basic (author-date)Patil SG (2022) A novel 2-metagene signature to identify high-risk HNSCC patients amongst those who are clinically at intermediate risk and are treated with PORT. MDPI, Basel
Juristische Zitierweise (Stüber) (Deutsch)Patil, Shivaprasad Gangadhar, A novel 2-metagene signature to identify high-risk HNSCC patients amongst those who are clinically at intermediate risk and are treated with PORT, Basel 2022.